Ann: Presentation of BIT225-009 HIV-1 Phase 2 Data, page-550

Not that I want to contribute to this upramping, but if BIT225 is part of a cure you can't use the current HIV market to estimate the value. If you cure people of HIV they stop taking the drugs. One of the reasons HIV has been such an attractive area to invest in by pharma companies is that the patients are on the drugs for life. The problem for the industry is there are now 25 anti-HIV drugs on the market and many of the best ones are off-patent or soon to go off patent. The future profitability of the HIV drug market is looking a lot less as the drugs go generic.

If you beleive BIT225 is part of a cure for HIV you need to look at HCV as a model, not HIV.